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Summary 
Preautoimmune New Zealand Black/White  (NZB/NZW)  mice immunized with Escherichia 
coli (EC) double stranded (ds) DNA produce antibodies that bind mammalian dsDNA and dis- 
play specificities similar to spontaneous lupus anti-DNA. Since calf thymus (CT) dsDNA fails 
to induce these antibodies, these results suggest a special potency of foreign DNA in inducing 
serological manifestations of lupus in a susceptible host. To assess the effects of DNA immuni- 
zation on clinical manifestations in NZB/NZW mice, we measured renal disease  and survival 
of mice immunized with either (a) EC dsDNA as complexes with methylated bovine serum al- 
bumin (mBSA) in adjuvant; (b) CT dsDNA with mBSA in adjuvant; (c) mBSA alone in adju- 
vant; or (d) unimmunized. After immunization with EC dsDNA, NZB/NZW mice developed 
significant levels of anti-dsDNA antibodies. Nevertheless, these mice had less proteinuria, ni- 
trate/nitrite  excretion, and  glomerular pathology than  mice  immunized with  either mBSA 
alone, CT dsDNA/mBSA complexes, or unimmunized mice. Survival of the EC dsDNA im- 
munized mice was significantly increased compared with the other mice. Furthermore, immu- 
nization of mice after the onset of anti-DNA production and proteinuria stabilized nephritis 
and prolonged survival. The improvement in renal disease  occurred despite the expression of 
autoantibodies  that bound mammalian  dsDNA  as well as  glomerular antigens.  These results 
suggest that bacterial DNA has immunological properties that attenuate murine lupus despite 
the induction of pathogenic antibodies. 
S  tLE is a prototypic autoimmune disease characterized by 
production of antibodies to DNA (anti-DNA, 1-3). 
These antibodies are markers for diagnosis and prognosis and, 
moreover, are closely linked to immunopathogenesis (4-6). 
A role of anti-DNA in lupus renal disease  is established by 
its concentration within the glomerulus as well as the fluc- 
tuation of its levels with disease activity (4-6). The basis for 
renal localization of anti-DNA is not yet certain, however, 
with  deposition of circulating immune  complexes, in  situ 
immune complex formation, and direct binding to cross- 
reactive glomerular antigens, all possible mechanisms (7, 8). 
Although  polyclonal  B  cell  activation  occurs  promi- 
nently in SLE and can stimulate autoantibody production, 
anti-DNA  expression appears  to be  the  result  of antigen 
drive  (9).  As  demonstrated  by  the  molecular  analysis  of 
monoclonal products  from  lupus  mice,  anti-DNA  show 
clonal expansion as well as somatic mutation (9, 10). These 
mutations are consistent with DNA as the in vivo selecting 
antigen since they enhance DNA binding (9,  10). Because 
mammalian DNA is poorly immunogenic in normal ani- 
mals,  this  analysis  further  suggests  that  lupus  involves  a 
unique responsiveness to DNA in susceptible individuals or 
stimulation by a form of DNA that is much more potent 
than the preparations used for experimental immunization 
(11-13). 
To gain further insight into the mechanisms of  DNA anti- 
gen drive,  our laboratories have  studied  the  immune  re- 
sponse to bacterial DNA  (14).  In  contrast to mammahan 
DNA, bacterial DNA is immunologically active and can in- 
duce polyclonal B cell activation as well as cytokine produc- 
tion in  the  mouse  (15,  16).  These immunological effects 
result from sequence arrays that differ between bacterial and 
mammalian  DNA  (17-19).  Although  the  immunological 
effects of bacterial DNA have been studied most extensively 
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ural  killer cell function and antibody production in humans 
(20, 21). 
In  previous  studies  (14,  22),  we  showed  that  bacterial 
DNA is highly immunogenic in normal mice under condi- 
tions in which mammalian DNA is inactive. Thus, BALB/c 
mice immunized with Escherirhia coli (EC) l double stranded 
(ds)  DNA  as complexes with methylated bovine serum al- 
bumin  (mBSA)  produce  antibodies that  bind  to  EC,  but 
not mammalian, dsDNA (14). Similarly, single stranded (ss) 
EC DNA  can induce antibodies specific for the immuniz- 
ing DNA,  although this DNA  form also elicits cross-reac- 
tive  anti-ssDNA  that  have  autoantibody  activity (22).  In 
contrast to results with normal mice, immunization ofpre- 
autoirmnune lupus-prone New Zealand Black/White (NZB/ 
NZW)  mice  with  EC  dsDNA  elicits true  autoantibodies 
that  bind  mammalian  dsDNA  as well as  the  immunizing 
DNA  (23). NZB/NZW  mice, however, do not respond to 
calf thymus  (CT)  dsDNA  immunization,  indicating  the 
unique  immunogenicity of foreign DNA  in  mice  predis- 
posed to autoimmunity (23). 
Although  they  lack  antibodies  to  mammalian  dsDNA, 
the serological hallmark of SLE, BALB/c mice immunized 
with EC DNA nevertheless develop mild immune complex 
glomerulonephritis (24). This lesion reflects the action of ei- 
ther antibodies to bacterial DNA or cross-reactive antibod- 
ies to mammalian ssDNA which arise during immunization. 
Because bacterial DNA  immunization  elicits anti-dsDNA 
autoantibodies in NZB/NZW  mice, we predicted that this 
intervention  would  intensify the  course  of their  autoim- 
mune disease (23). As reported herein, we have studied the 
effects of bacterial DNA on murine lupus and found, unex- 
pectedly, that immunization with EC dsDNA prolongs sur- 
vival and reduces glomerulonephritis in NZB/NZW  mice 
despite induction of anti-DNA. These findings thus estab- 
lish a  novel action of bacterial DNA  and suggest that mi- 
crobial products  may retard  specific manifestations  of au- 
toimmunity. 
Materials and Methods 
Mice.  Female NZB/NZW  mice were  obtained at 6  wk  of 
age from The Jackson Laboratory (Bar Harbor, ME)  and main- 
tained under standard conditions in the animal facility of Durham 
VA Medical Center. 
DNA.  EC and CT DNA were purchased from Sigma Chem- 
ical Co.  (St. Louis, MO) and further purified by phenol extrac- 
tion. For these experiments, dsDNA was obtained by digestion of 
the DNA with $1 nuclease (Sigma Chemical Co.). DNA concen- 
tration was determined by OD 260 absorbance whereas purity of 
DNA was  determined by the OD 260/280  ratio. DNA used in 
these  experiments all had a  ratio of >1.9.  LPS  content of the 
DNA preparations as measured by the Limulus amebocyte assay 
BioWhittaker, Walkersville, MD) varied from 6 to 10 ng/ml for 
~Abbreviations used in this paper: CT, calf thymus; ds, double stranded; EC, 
Escherichia coli; mBSA, methylated bovine serum albumin; N/N, nitrate/ 
nitrite;  NO,  nitric  oxide;  NZB/NZW,  New  Zealand  Black/New 
Zealand White; ss, single stranded. 
EC DNA (1-3 mg/rnl of DNA) and from 0 to 3 ng/ml for CT 
DNA (0.5-1  mg/ml of DNA). The LPS assays were performed 
according to the manufacturer's protocol using standards of known 
concentrations of LPS. 
Immunizations.  Groups of five to ten 7-8-wk-old NZB/NZW 
female mice were immunized with DNA as previously described 
(14). Briefly, mice were immunized intraperitoneally with 0.3 cc 
of an emulsion of Freund's adjuvant containing 50 txg of either 
EC or CT dsDNA complexed with 75 I~g ofnfl3SA. Mice were 
immunized three times at 2-wk intervals. The first immunization 
used  CFA  whereas  the  two  booster immunizations  used  IFA. 
Control groups consisted of five mice immunized with mBSA in 
adjuvant alone and five unimmunized mice. The immunization 
experiments were performed three separate times using different 
groups of mice and different lots of DNA. 
In one of the experiments, a cohort of NZB/NZW mice was 
monitored every 2 wk with 24-h urine collections. When pro- 
teinuria exceeded 2 rag/mouse/day, the mice were divided into 
groups and immunized with EC dsDNA/mBSA or mBSA alone 
in adjuvant. Another control group was unirnmunized. 
Urine Studies.  Mice were placed in metabolic cages either weekly 
or biweekly for 24-h  collecfons of urine using collection vials 
containing an antibiotic solution to prevent bacterial growth. Af- 
ter collection, urine was maintained at  -70~  until testing for 
protein or nitrate/nitrite (N/N)  content.  Protein was measured 
using the Bio-Rad assay (Richmond, CA) according to the man- 
ufacturer's instructions. Urinary N/N, a measure of nitric oxide 
(NO) production, was determined spectrophotometrically using a 
previously described technique (25).  Mice undergoing measure- 
ment of urinary N/N were placed on a N/N-free diet (Zeigler 
Brothers, Gardners, PA) during the study period. 
ELISA.  Serum was obtained before immunization and 1 wk 
after the last immunization in all groups. In certain immunization 
groups, sera were obtained monthly until the mice were 6-7 mo 
of age. Mice were bled from the retroorbital sinus after methoxy- 
flurane inhalation anesthesia. 
Serum anti-dsDNA activity was determined by ELISA using pre- 
viously published techniques  (14). Briefly, 96-well polystyrene plates 
(Dynatech Laboratories, Inc.,  Chantilly, VA)  were  coated with 
100  Ixl/well ofdsDNA (either EC or CT) at a concentration of 
5 p~g/ml in SSC (0.15 M NaC1,  0.015 M  Na citrate, pH 8) over- 
night at 37~  Plates were blocked with 1% BSA in PBS before 
adding serial dilutions of sera starting at a dilution of 1/100  in 
PBS-Tween/l% B SA. After washing, peroxidase-conjugated goat 
anti-mouse  lgG  0/  chain  specific,  Sigma  Chemical  Co.)  was 
added, followed by 3,3',5,5' tetramethylbenzidene diluted 1/100 
in 0.l  M  citrate, pH 4  with 0.015%  H202.  Absorbance at OD 
380 was determined on a UVmax microtiter plate reader (Molec- 
ular Devices Corp., Menlo Park, CA). 
The isotype of the anti-DNA response in individual sera was 
performed by ELISA as described above, except that isotype-spe- 
cific  conjugates  (Southern  Biotechnology Associates, Birming- 
ham, AL) were used. The conjugates were titered to assure  that 
equal amounts of each IgG isotype were detected in the ELISA. 
Inhibition assays were performed to determine relative affinity 
of DNA binding as previously described (26). Briefly, sera at dilu- 
tions yielding an OD 380 absorbance of 1 were incubated for 45 
rain with CT dsDNA at various concentrations starting at 50 txg/ 
hal. After the  incubation period,  the  sera/DNA mixtures were 
added to microtiter plates coated with CT dsDNA as described 
above,  and bound  antibody measured.  The  percent inhibition 
was  calculated by subtracting the inhibited absorbance from the 
uninhibited absorbance divided by the uninhibited absorbance. 
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7  rot.  At the  time of killing,  the  kidneys  were  removed.  One 
kidney was placed in 10% buffered formalin, fixed in paraffin, and 
sectioned before staimng with hematoxylin and eosin. The other 
kidney was quick frozen in liquid N2, fixed, and sectioned before 
staining with fluorescein-conjugated goat anti-mouse IgG (Sigma 
Chemical Co.). 
Glomerular  disease  was  graded  by  a  pathologist  (P.  R.uiz) 
blinded as to the group  of origin of the kidney sections.  Scores 
were determined using a grading system we have previously de- 
scribed that  assign 0-3+  scores for proliferation,  necrosis,  cres- 
cent  formation,  vasculitis,  and  inflammatory  infiltrate  (27).  IgG 
deposition was graded 0-3+  on the fluorescent slides by the same 
blinded pathologist. 
Glomerular Binding Assay.  Sera were assessed  for their ability 
to bind to glomeruli in an in vitro assay  as previously described 
(28).  Briefly,  glomeruli were  derived from saline-perfused  kid- 
neys from Lewis rats  by a sieve technique.  Glomeruli were per- 
meabilized with collagenase type II and DNase in Hank's salt so- 
lution and  then vacuum affixed to a  nitrocellulose filter using a 
Bit-Dot  apparatus  (Bio-P,  ad  Laboratories).  Sera were  added  at 
1/100  dilutions.  Goat  anti-mouse  IgG  (Bio-R.ad  Laboratories) 
was then added, followed by a secondary alkaline phosphatase con- 
jugate, and standard chloronaphthol solution (Bio-P,  ad Laborato- 
ries).  A  quantitative value was obtained by determining the den- 
sity of the derived dots.  All assays were performed in duplicate. 
The  absorption  of a  control positive serum from a MP,.L-lpr/lpr 
mouse was assigned a value of 100.  A  negative control BALB/c 
sera was assigned a value of 0. 
Statistics.  Statistical values for anti-DNA production, proteinuria, 
N/N excretion, and renal scores were determined using the Mann- 
Whitney two-tared U  test. Survival statistics were analyzed using 
the log-rank sum method. 
Results 
To determine the effects of bacterial DNA  immunization 
on murine lupus, we first assessed serological findings of fe- 
male NZB/NZW  mice immunized with either EC dsDNA 
complexes with mBSA, CT dsDNA complexes with mBSA, 
or mBSA  alone in  adjuvant.  Mice  of this  strain  develop  a 
genetically determined syndrome  at 5-6 mo of age that re- 
sembles  SLE in the  occurrence  of anti-DNA  and  immune 
complex-mediated  renal  disease  (29).  In  confirmation  of 
previous  results,  we  found  that  8-wk-old  NZB/NZW 
mice  immunized  with  EC  dsDNA/mBSA  complexes  de- 
velop a prompt anti-dsDNA response that includes autoan- 
tibodies that  bind  CT  as well as EC  dsDNA  (23).  In con- 
trast,  NZB/NZW  mice  immunized  with  CT  dsDNA/ 
mBSA or mBSA alone lacked significant antibody produc- 
tion (Fig.  1). 
To determine the effect of DNA  immunization  on renal 
disease,  serial urine  samples  were  assessed for 24-h protein 
excretion.  Previous  studies  (30)  have  shown  that  NZB/ 
NZW  mice develop early renal  disease when  treated with 
polyclonal B  cell activators. Consistent with these earlier ob- 
servations,  mice  immunized  with  mBSA  or  CT  dsDNA/ 
mBSA  in  adjuvant  had  the  onset  of proteinuria  (>2  mg/ 
mouse/day)  at 14 wk of age. Proteinuria continued in these 
groups  until  at  least  17  wk  of age  when  the  mice  were 
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Figure  1.  Anti-DNA production  by immunized  NZB/NZW mice. 
Data shown are the mean 380-nm absorbance •  the standard deviation of 
five sera in each group using CT dsDNA as the antigen in an ELISA. Sera 
were obtained  2  wk after the final immunization (14 wk of age). The 
anti-DNA response is significantly greater (P <0.05) in the EC dsDNA/ 
mBSA immunized group  (squares) than in the CT dsDNA/mBSA group 
(circles)  or mBSA group (diamonds) at all sera dilutions. 
killed. Because of the similarities in these two groups, the data 
are presented together in Fig. 2.  In contrast,  over the same 
time  period,  none  of  the  mice  immunized  with  EC 
dsDNA  developed proteinuria  >  1 mg/mouse/day.  Before 
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Figure 2.  Urinary protein excretion of immunized NZB/NZW mice. 
Data presented are the mean 24-h protein excretion +  the standard devi- 
ation  plotted against the age of the mice in weeks.  (Open circles) Com- 
bined data for the mBSA (n =  5) and the CT dsDNA/rnBSA immunized 
mice (n =  5). Two mice in this group died at 15 wk and two additional 
mice died at 16 wk. The remaimng six mice were killed at 17 wk of age. 
(Squares) Protein excretion of mice immunized with EC dsDNA (n = 
10). At 17 wk of age, five mice were killed in parallel with the mBSA/ 
CT dsDNA group for pathologic studies. The remaining five mice in this 
group were followed until 25 wk of age. (Closed dr&s) Protein excretion 
by unimmunized NZB/NZW  mice  (n  =  5).  These  mice were killed 
along with the five remaining  EC dsDNA immunized mice at 25 wk of 
age for pathologic studies. (Arrows) Two peaks ofproteinuria. 
1391  Gilkeson et al. Table  1.  Urinary  N/N Excretion by NZB/NZW  Mice  Table 2.  Effects  of  DNA Immunization  on Renal Disease in 
NZB/NZW  Mice 
Urinary nitrate/nitrite 
Week  8  15  25 
/~M 
EC DNA immunized  0 -+ 0  0.4 -  0.1  0.1  _+ 0 
mBSA/CT DNA immunized  0 -+ 0  10.0  •  3.1  ND* 
Unimmunized  0 _+ 0  0 q- 0  13.1  +  3.2 
Mice were fed a N/N-free diet and 24-h urine was collected in meta- 
bolic cages. Data presented are the mean 24-h urinary N/N excretion 
+  standard deviation for 10 mice in the immunized groups and 5 mice 
in the unimmunized group. At 17 wk of  age, five mice in the EC DNA 
group and the remaining six mice (four mice died in these groups) in 
the mBSA/CT DNA group were killed. The difference in urinary N/ 
N excretion between the EC DNA immunized group and the mBSA/ 
CT DNA group at week 15 is statistically  significant (P <0.05); the dif- 
ference between  the EC DNA group and the unimmunized  group at 
week 25 is statistically  significant (P <0.05). 
*Mice in this group were killed at 17 wk of age. 
killing,  two  of five  mice  in  each  of the  mBSA  and  CT 
dsDNA  groups  died.  None  of 10  mice  immunized  with 
EC dsDNA died, however. 
Urinary N/N  can be used as a marker of inflammation 
since, with animals on a N/N-free diet, levels of these mole- 
cules reflect total body NO  production. As previously dem- 
onstrated, N/N  levels are dramatically increased in MRL-Ipr/ 
lpr mice, another lupus-prone strain with glomerulonephri- 
tis (25).  In the present experiments, a sharp increase in N/ 
N  followed immunization of all animals (data not shown). 
This production most likely reflects acute inflammation in- 
duced  by  adjuvant.  After  decline  in  these  levels back  to 
baseline,  N/N  excretion  rose  again  in  mice  immunized 
with mBSA or mBSA/CT  dsDNA. These elevations paral- 
leled the increase in proteinuria (Table 1). In contrast, mice 
immunized with EC dsDNA/mBSA had low levels of uri- 
nary N/N  at the same time point, consistent with the lack 
of proteinuria. 
Kidneys obtained from mice killed at 17 wk of age were 
examined histologically. As shown  in  Table 2  and  Fig.  3, 
glomerular disease was significantly less in the EC  dsDNA 
immunized mice than the CT  dsDNA and mBSA immu- 
nized groups. Immunofluorescence staining of the kidneys, 
however,  revealed 3+  IgG  deposition in  the  mesangium 
and glomerular loops in the kidneys of all three groups. 
An additional group  of five mice  immunized  with  EC 
dsDNA/mBSA was followed after 17 wk of age along with 
unimmunized  control  mice.  As  shown  in  Fig.  2,  urinary 
protein excretion in the unimmunized mice began after 19 
wk of age and continued until 25 wk of age when the ani- 
mals  were  killed.  In  the  EC  dsDNA  group,  proteinuria 
never exceeded 1 rag/mouse/day. Urinary N/N  excretion 
was also significantly higher in the unimmunized group than 
in  the  mice  immunized  with  EC  dsDNA  (Table  1).  As 
shown  in  Table  2,  mice  immunized  with  EC  dsDNA/ 
mBSA  had  significantly lower glomerular scores  than  the 
Group (17-wk-old)  EC dsDNA  mBSA  CT dsDNA 
Renal score  1.6 --- 0.4  3.9 +  1.3  3.3 +  0.8 
Glomerular IgG  3 +  3 +  3 + 
Group (25-wk-old)  EC dsDNA  Unimmunized 
Renal score  3.5 -  1.2  7.5 __+ 2.8 
Glomerular IgG  3 +  3 + 
Data presented are the mean renal score  +  standard deviation of five 
mice in each group. Glomerular IgG data are presented as the degree of 
immunofluorescence.  The difference between the glomerular scores of 
the EC DNA group and the mBSA/CT DNA groups is statistically  sig- 
nificant (P <0.05);  the difference in scores between the EC DNA and 
unimmunized group at 25 wk is also statistically  significant (P <0.05). 
unimmunized group  despite similarities in glomerular IgG 
deposition. Together, these results indicate that immuniza- 
tion with EC dsDNA/mBSA complexes blocks the devel- 
opment of early renal disease that results from adjuvant ef- 
fects as well as the spontaneous disease that develops with age. 
A  second set of in~rnunizations was performed using dif- 
ferent lots of DNA, rnBSA, and adjuvant.  Confirming the 
previous experiment, the mice immunized with EC dsDNA/ 
mBSA  developed  significantly less  proteinuria  than  mice 
immunized with mBSA alone (Table 3). The EC dsDNA/ 
mBSA  immunized  mice  also  had  significantly  decreased 
mortality compared with either mice immunized with mBSA 
alone (Fig. 4 A) or unimmunized mice (Fig. 4 B). 
To determine ifEC dsDNA immunization could modify 
established autoimmune  disease,  we  immunized  5-6-too- 
old NZB/NZW  mice that had proteinuria and high anti- 
DNA  levels.  In  these  experiments,  control mice  received 
either mBSA or were unimmunized.  Although mice in all 
three groups had high anti-dsDNA levels, proteinuria in the 
EC dsDNA group stabilized after immunization whereas pro- 
teinuria in  the  other groups  steadily increased;  there  was, 
however, no statistically significant difference in proteinuria 
between the groups after immunization.  Survival was pro- 
longed, however, in the EC dsDNA group compared with 
the other two groups (Table 4). 
We next investigated whether EC dsDNA immunization 
altered the pathogenicity of the expressed anti-DNA anti- 
bodies.  Avidity of the  induced  anti-DNA  was  similar to 
spontaneous anti-DNA as shown by inhibition binding stud- 
ies. Thus,  for the induced antibodies, 50% binding inhibi- 
tion required  12  +  5  p~g/ml of CT dsDNA whereas anti- 
bodies arising spontaneously required 11  --+ 4 p,g/ml (n ---- 5 
sera for each  group).  The  induced  and  spontaneous  anti- 
bodies  also  had  a  similar isotype  distribution,  since  both 
displayed a  predominance  of IgG2a and  IgG2b antibodies 
(Table 5).  Finally, as shown in Table 6,  sera from  the EC 
dsDNA  immunized  mice  bound  to  glomerular  antigens 
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ogy in NZB/NZW mice. Rep- 
resentative photomicrographs of 
glomeruli from:  (A)  17-wk-old 
mBSA immunized NZB/NZW 
mouse,  demonstrating  marked 
glomerular  proliferation  with 
acute and chronic inflammation 
(renal score of 7);  and  (B)  17- 
wk-old EC dsDNA/mBSA  im- 
munized  NZB/NZW  mouse, 
demonstrating minimal prolifera- 
tive changes without  inflamma- 
tion (renal score of 1.5). Photo- 
micrographs are enlarged X79. 
better than  sera from  the  mBSA immunized  or unimmu- 
nized groups immediately after immunization, whereas sera 
from all three groups at 5--6 mo of age bound to glomeruli 
similarly. Since  this  in  vitro  assay correlates with  in  vivo 
glomerular binding and pathogenicity, these findings sug- 
gest  that  renal  protection  caused  by  immunization  with 
bacterial DNA  does not  result from  a  shift in  the  immu- 
nochemical  properties  of  anti-DNA  or  elimination  of 
pathogenic specificities. 
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Discussion 
Results of these experiments indicate that immtmization of 
preautoimmune NZB/NZW  mice with EC dsDNA/mBSA 
complexes can profoundly alter the course of their disease. 
These  changes  occur  despite the  expression of anti-DNA 
that  resemble  spontaneous  anti-DNA  in  their  specificity, 
avidity, isotype, and ability to bind to glomeruli. Further- 
more, immunization with EC dsDNA/mBSA after the on- 
set  of renal  disease  can  stabilize proteinuria  and  prolong Table 3.  Effect of DNA  Immunization  on Proteinuria 
in NZB/NZW  Mice 
Group  Proteinuria 
dsEC DNA (n =  10) 
mBSA immunized (n =  5) 
Unimmunized (n =  10) 
0.8 -  0.6 
5.0 -- 0.1 
4.2 -+ 3.6 
Data presented are the mean 24-h protein excretion in milligrams/day/ 
mouse + standard deviation of  NZB/NZW mice at 25 wk of  age. The 
difference in proteinuria between the EC DNA immunized group and 
the mBSA  and unimmunized groups was significant at p <0.05. 
survival.  Together,  these  findings  suggest  that  foreign 
DNA, while provoking serological abnormalities,  can nev- 
ertheless attenuate manifestations of autoimmunity. 
Although DNA has generally been considered immuno- 
logically inert,  recent  studies  (13-19)  demonstrate  clearly 
that bacterial DNA is active in mice and can induce cyto- 
kine  production  as  well  as  polyclonal  B  cell  activation. 
These effects result from palindromic sequence motifs that 
consist of an unmethylated CpG flanked by two 5' purines 
and two 3' pyrimidines  (17-19).  This motif is common in 
bacteria DNA and rare in mammalian DNA (19).  Further- 
more, methylation of cytosine in bacterial DNA eliminates 
mitogenicity (19). Because of differences between mamma- 
lian and bacterial DNA in their pattern of cytosine methy- 
lation,  a  basis  for immune  recognition  of DNA  is  estab- 
lished. 
Since polyclonal B  cell activators accelerate  autoimmu- 
nity in NZB/NZW  mice, the reduction of renal disease by 
bacterial DNA is probably unrelated to this activity (30).  It 
is more likely that the therapeutic effects of bacterial DNA 
result from changes in the cytokine milieu and the balance 
of regulatory T  cell subsets in treated animals. NZB/NZW 
mice produce low levels of TNF-ot due to a deletion in the 
gene for this cytokine (31). Although genetic evidence sug- 
gests that this defect may promote autoimmunity, a role of 
TNF-ot  in  glomernlonephritis  is  shown  directly  by treat- 
ment  studies  with  recombinant  cytokine  (32,  33).  Thus, 
chronic  administration  of TNF-ot  to  NZB/NZW  mice 
leads  to improvement in  renal  disease.  This  effect is  dose 
dependent  since  higher  doses  of TNF-et  decrease  disease 
severity (32, 33). 
In in vitro studies, both EC DNA and synthetic oligonu- 
cleotides with active palindromic sequences induce TNF-a 
and IL-12 production by murine splenocytes (34). It is pos- 
sible, therefore, that bacterial DNA immunization increases 
TNF-o~  and  thereby  decreases  renal  disease  in  a  manner 
similar to exogenously administered recombinant cytokine. 
Alternatively,  changes in  other  cytokines,  e.g.,  IL-12 and 
IFN-~/production,  may alter  the  Thl/Th2  ratio  in  these 
mice  or  otherwise  modify  immune  responsiveness  and 
thereby affect clinical disease. 
At present,  the  range  of cytokines induced by bacterial 
DNA is  unknown,  and it is possible  that  effects  on other 
cytokines alone or together reshape  the immune  environ- 
ment in autoimmune  mice.  The  effects  of bacterial  DNA 
ultimately  modify the  generation  of inflammatory media- 
tors  since,  as  we  have  shown,  NZB/NZW  mice  immu- 
nized with bacterial DNA have reduced NO production. It 
is of interest  in this regard that bacterial DNA immuniza- 
tion  can  block  spontaneous  renal  disease  as  well  as  renal 
disease induced by administration of adjuvant,  suggesting a 
generalized anti-inflammatory effect. 
The effects  of immunization with foreign DNA may vary, 
however,  depending  on  the  source  of the  DNA  and  the 
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Figure 4.  Survival  of immunized and unimmunized NZB/NZW mice. Data presented are the number of mice surviving plotted against the age in 
months. (A) Survival of 10 mice immunized with EC dsDNA/mBSA (solid line) versus 10 mice immunized with mBSA alone (dashed line). Survival in the 
EC DNA group was significandy  greater (P = 0.03). (Arrows) Time ofimrnunizations. (B) Survival of 10 mice immunized with EC dsDNA/nfl3SA  (solid 
line) versus 10 unimmunized mice (dashed line). Survival in the EC DNA group was significantly  greater (P = 0.04). Statistical analysis was performed us- 
ing the log-rank sum test. (Arrow) Time of the initial immunization. 
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Proteinuria 
Preimmunization  Postimmunization  Anti-DNA  Survival 
EC DNA  7.7  +  1.3  4.3  +  2.1  1.586 -+ 0.493  4/5 
(n =  5) 
mBSA  1.4 4- 0.4  3.7  +  1.8  1.295 +  0.489  0/5 
(.  =  5) 
Unimmunized  4.2 +  2.4  5.7 +  1.6  1.135 +  0.311  1/5 
(,,  =  5) 
Data presented are the mean 24-h protein excretion +  standard deviation, preimmunization, and 2 wk postimmunization. Anti-DNA data are the 
ELISA results in terms ofabsorbance + standard deviation ofsera obtained 1 wk after the final immunization. Survival  data are presented in terms of 
mice alive at 9 mo of age. There was no statistical  difference in postimmunization proteinuria and anti-DNA levels between groups. The difference 
in survival of the EC dsDNA/mBSA immunized group versus the other two groups approached statistical  significance  using the log-rank sum test 
(P =  0.06). 
content of sequences with  immunomodulatory potential. 
Frederiksen et al.  (35)  have shown that DNA from the BK 
polyomavirus can stimulate the production of antibodies spe- 
cific for nonconserved sites on viral DNA in normal mice, 
whereas in NZB/NZW  mice, immunization  elicits antibodies 
cross-reactive with mammalian DNA.  These  findings are 
similar to our results with EC DNA.  In contrast to results 
reported herein, however, immunization  with the BK viral 
DNA  accelerates  renal disease  (35).  Thus,  although both 
EC  and BK DNA stimulate an early anti-DNA antibody 
response,  they  must have  divergent effects  on  other  im- 
mune cells (i.e., macrophages and T  cells)  resulting in dis- 
parate chnical outcomes. 
Because the DNA used in these experiments was derived 
from bacteria, we have been concerned about the impact of 
any contamination by LPS on the in vivo responses, since 
this bacterial product can provoke changes in the murine 
immune system. We have therefore used extensively puri- 
fied DNA preparations with minimal contamination  by LPS 
as  assessed  by the  Limulus amebocyte assays  (15).  As  we 
have previously shown, in no instance can we account for 
any in vivo  or  in vitro  effects  of bacterial DNA  by  this 
amount of LPS (14, 15,  18, 22). Furthermore, all immuno- 
modulatory effects of bacterial DNA have been reproduced 
with synthetic oligonucleotides and polynucleotides that are 
free  of contaminating bacterial products  (17-19,  34).  The 
effects of bacterial DNA are also unaffected by polymyxin 
B, although fully sensitive to digestion by DNase (15). 
Even if our DNA preparations had enough LPS  to in- 
duce in vivo effects, we predicted the  outcome to be the 
opposite  of the  renal  protection  observed.  As  shown  in 
many studies, LPS  causes polyclonal B  cell activation and 
glomerulonephritis in  normal mice,  whereas,  in  autoim- 
mune strains,  it  accelerates  autoantibody production and 
glomemlonephritis  (36-42).  Treatment  of  mice  with  a 
combination of LPS  and CT DNA  also leads  to  an early 
onset of glomerulonephritis (43).  In this  regard,  doses  of 
LPS  <20  p~g had minimal effect on antibody production, 
although these levels were far greater than those present in 
our DNA preparations (36). Taken together, these consid- 
Table 5.  Isotype of the Induced Anti-DNA Response in NZB/NZW  Mice 
Isotype  IgG1  IgG2a  IgG2b  IgG3 
EC DNA immunized  17.1 -+ 5.5  35.2 +  5.9  43.6  +  11.3  3.9  +  4.1 
(n =  10) 
mBSA immunized  32.7 _.T_ 24.1  24.6 +  25.7  40.7  +  22.5  4.2  +  8.1 
(n =  7) 
Unimmunized  21.2 -+ 8.1  31.9  +  10.1  36.3  +  7.7  9.0 +  11.1 
(n =  6) 
Data presented are the mean percentage -+ standard deviation of the total IgG anti-DNA for each isotype. Sera were obtained at 14 wk of age in the 
EC DNA and mBSA immunized groups and at 25 wk of age in the unimmunized group. 
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Group  14 wk  25 wk 
EC dsDNA immunized  67.3  +  14.1  57.7  _+ 3.2 
mBSA immunized  28.5  _+ 10.4  42 
Unimmunized  14.0 -  7.7  48.3  +  16.7 
Data presented are the sera mean glomerular binding score +  standard 
deviation of five sera in each group. There was only one sera available 
for testing at 25 wk in the mBSA immunized group. The glomerular 
binding by the EC dsDNA immunized group at 4 mo of age was sig- 
nificantly  greater than that of the other two groups at p <0.05. 
erations suggest that it is highly unlikely that LPS  in our 
EC  DNA  preparations  caused  the  renal protective  effect 
observed. 
Infection has long been considered an etiologic factor in 
the pathogenesis of SLE as well as other autoimmune dis- 
eases.  Whereas most investigation has focused on the po- 
tentiating influences of microbial products on these condi- 
tions, such molecules may also have inhibitory influences, 
as these studies indicate. Whether bacterial DNA can play 
such a role is uncertain, although the consequences of this 
molecule likely vary, depending of the status of the host. 
While pointing to novel immunomodulatory  approaches 
in SLE,  these studies also have implications for the  use of 
nucleic  acids  in  the  therapy  and  prevention  of disease. 
DNA constructs are being tested as vehicles for the intro- 
duction  of genetic  material  to  correct  inherited  defects, 
augment resistance to tumors, and provide a source of anti- 
gen for  vaccination (44).  Since many of these  constructs 
have sequences from bacterial plasmids, they may promote 
in vivo immune alterations that could affect the  result of 
gene therapy as well as induce the immune system to pro- 
mote or restrain inflammatory disease. 
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